RenovoRx’s PanTheR Post-Marketing Registry Study Progresses with First Clinical Procedure and Addition of Two Participating Clinical Sites
RenovoRx today announced that the first registry-eligible patient procedure in its PanTheR Post-Marketing Registry Study (NCT06805461) has been successfully completed at the University of Vermont Cancer Center.